Biotech Gets Its Mojo Back While AI Infrastructure Stumbles
Biotech Gets Its Mojo Back While AI Infrastructure Stumbles
The ACCE Biotech Catalysts index jumped 1.20% this week, its best performance in six weeks, driven by SRPT’s 8.3% surge on renewed FDA optimism and VRTX holding steady despite profit-taking pressure. Meanwhile, our AI Infrastructure index slipped 0.27% as NVDA gave back early gains and cloud names like NET and DDOG faced growth multiple compression.
Big Picture
The rotation out of AI darlings and into biotech isn’t just noise. It’s recognition that the easy money in AI infrastructure has been made, while biotech sits at an inflection point, with FDA approvals accelerating and valuations still reasonable. Our Biotech index trades at 18x forward earnings versus 28x for AI Infrastructure, yet biotech’s pipeline visibility extends further than most AI revenue models.
The FDA approved 47 new drugs in Q1 2026, up 23% year-over-year, with gene therapies leading the charge. That’s creating a tailwind for our biotech holdings, particularly SRPT, which we added to the index this week at a 5.5% weight. The company’s gene therapy for Duchenne muscular dystrophy is on track for approval, with Phase III data showing a 40% improvement in muscle function versus placebo.
But the real story is capital allocation. Biotech companies are finally learning to say no to marginal programs and yes to focused bets. VRTX exemplifies this shift, shuttering three early-stage programs last quarter to double down on its cystic fibrosis franchise expansion.
Portfolio Update
We made structural fixes across three indices this week, all driven by concentration limits rather than by changes in investment thesis. The Biotech index needed a seventh holding to meet minimum requirements, so we added SRPT at 5.5% while trimming VRTX from 25.5% back to the 20% cap. SRPT was already in our picks book with a $52 target on a $21 entry, making this an easy call.
Quality Compounders saw bigger changes. We trimmed AAPL from 21.6% to 15% and COST from 18.2% to 15%, then added MSFT and GOOGL to bring the index to eight holdings. The AAPL trim hurts given the stock’s 12% run this month, but concentration discipline matters more than short-term performance.
Our Defense & Aerospace index required two separate rebalancing moves as LMT and NOC both breached the 15% single-name limit. We redistributed 5% to Boeing, which has outperformed the sector by 16.4% this month following its April 22 earnings beat. Boeing’s commercial aircraft backlog hit $380 billion, up 8% sequentially, while defense margins expanded to 12.1%.
The AI Infrastructure trim was more surgical. We reduced NVDA from 16.1% to 15% and MSFT from 13.4% to 12.3%, redeploying the 2.2% to double AMZN’s weight from 2.2% to 4.4%. Amazon’s cloud growth reaccelerated to 19% in Q1, and its AI services revenue run rate hit $2.1 billion.
Pick of the Week Preview
This week’s pick is a 24,500-employee precision measurement giant trading three weeks ahead of a major catalyst. The company is spinning off its lower-growth software division as Octave Intelligence on May 22, leaving behind a pure-play hardware business with 40% higher margins and a $4.2 billion addressable market in industrial automation.
The parent trades at 14x forward earnings despite 23% ROE and a net cash balance sheet. Sum-of-the-parts analysis suggests 35% upside to our $118 target, with the spin creating immediate recognition of value. Management has forecasted $850 million in annual cost synergies after separation, while the rest of the business maintains premium multiples in similar transactions.
On Our Radar
We’re watching MRNA closely after the EU approved its combination flu-COVID vaccine despite the company posting a $1.3 billion Q1 loss. The vaccine could generate $2-3 billion in annual revenue by 2028, but execution risk remains high given manufacturing complexity.
RTX’s 7.4% dividend increase signals confidence in its defense backlog, now at $206 billion. The stock trades at 16x earnings and yields 8% free cash flow, but we need clarity on Pratt & Whitney engine inspection costs before adding exposure.
SNOW’s insider selling accelerated this week with $8.38 million in Form 144 filings. The stock has rallied 28% since the March lows, but concerns about growth deceleration persist as enterprise customers optimize cloud spending.
The biotech sector's momentum appears sustainable due to upcoming pipeline catalysts and reasonable valuations, whereas AI infrastructure confronts more challenging comparisons and potential multiple compression. Our positioning reflects these trends.